Oxcarbazepine versus Divalproex Sodium for the Continuing Treatment of Mania

Clinical Drug Investigation

Volumn 23, Issue 10, 2003, Pages 671-677

  Reinstein, Michael J ^a   Sonnenberg, John G ^a   Hedberg, Thomas G ^a   Jones, Lynne E ^a   Reyngold, Polina ^a  

^a Uptown Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXCARBAZEPINE; TRANQUILIZER; VALPROATE SEMISODIUM;

ADULT; ARTICLE; ATAXIA; BODY WEIGHT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; NERVOUSNESS; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZATION; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; VERTIGO; VOMITING;

EID: 0142042418     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200323100-00006     Document Type: Article

References (16)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: APA Press, 1994
2. Maj M, Pirozzi RM, Lorenza-Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998; 155: 30-5
3. Tondo L, Baldessarini R, Hennen R, et al. Lithium maintenance treatment of depression and mania in bipolar I and bipolar II disorders. Am J Psychiatry 1998; 155: 638-45
4. Dunn RT, Frye MS, Kimbrell TA. The efficacy and use of anticonvulsants in mood disorders. Neuropharmacology 1998; 21: 215-35
5. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder: Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57: 481-9
6. McElroy SL, Keck PE. Pharmacologic agents for the treatment of acute bipolar mania. Biol Psychiatry 2000; 48: 539-57
7. Depakote package insert. North Chicago (IL): Abbott Laboratories 2002
8. Griel W, Krueger R, Rossnagl G. Prophylactic treatment of affective disorders with carbamazepine and oxcarbazepine: an open clinical trial. In: Pichot P, editor. Pharmacopsychiatry New York, Plenum Press, 1983: 491-4
9. Velikonja M, Heinrich K. Effect of oxcarbazepine on affective and schizoaffective symptoms, a preliminary report. In: Emrich HM, Okuma T, Muller AA, editors. Anticonvulsants in affective disorders. Amsterdam: Pergamon Press, 1984
10. Cabrera JF, Muelbaurer HD, Schley J. Long-term randomized clinical trial of oxcarbazepine vs lithium in bipolar and mood disorders: preliminary results. Pharmacopsychiatry 1986; 19: 282-3
11. Emrich HM, Altmann H, Dose M, et al. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord 1985; 8: 243-50
12. Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994; 35: 10-3
13. Baruzzi A, Albani F, Riva R. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 1994; 35: 14-9
14. McLean MJ, Schmutz M, Wamil AW, et al. Oxcarbazepine: mechanisms of action. Epilepsia 1994; 35 Suppl. 3: S5-9
15. Altman EG, Hedeker DR, Janicak PG, et al. A clinician-administered rating scale for mania. Biol Psychiatry 1994; 36: 124-34
16. Trileptal package insert. East Hanover (NJ): Novartis Pharmaceuticals Corporation 2001